12mins - Expert presentations By Lars Bastholt
Treatment of Metastatic Melanoma in 2019
As a leading expert in the field of metastatic melanoma, Lars Bastholt runs through the recent developments that have transformed treatment of this disease and vastly improved average prognosis. He covers the major trials of drugs targeting the activated MAPK pathway and those blocking CTLA4 and PD1. There is information on which toxicities to look out for with particular regimens, as well as useful guidance on selecting the most appropriate treatment according to patient factors such as disease aggressiveness and molecular biomarkers. Finally, Professor Bastholt looks to trials in progress and how treatment may change in the near future.
17mins - Expert presentations By Mike Youle
Maintaining and optimising long term ARV therapy
In this expert presentation, Professor Mike Youle, Royal Free Hospital, London discusses how antiretroviral therapy (ART) for people with HIV has changed over the years. He considers the issues that he takes into account to ensure the long term health of patients.
14mins - Expert presentations By Thierry Naas
Epidemiology of multidrug resistant Gram-negative bacteria: Are we close to the « post antibiotic era »?
Multidrug resistant bacteria are developing so fast that the burden of deaths due to these bacteria could be 10 million lives/year by 2050 - with an estimated cost of 1,000 trillion USD! In this short presentation, Dr. Naas highlights this crucial problem by explaining the mechanisms behind Gram-negative bacteria resistance as well as the epidemiology of extended spectrum ß-lactamase and carbapenem-resistance. He also presents possible solutions that can be used in this time-sensitive fight.
9mins - Expert presentations By Vicky Tittle
Dr Vicky Tittle, from 56 Dean Street in London, UK, reviews the reasons to test for HIV, when and how to test and which key populations should receive testing. Specific focus is placed on British guidelines for HIV testing and importance to conduct key initial investigations.
13mins - Expert presentations By Professor David Livermore
Future developments in antimicrobial agents
Professor David Livermore highlights increasing resistance and the major bacterial challenges we face. Beta-lactams, the most widely used antibiotic are losing their efficacy. However, there is hope for antimicorbial agents. Cefiderocol, murepavadin and gepotidacin/zoliflodacin all show promise in replacing spent antibiotics. Further, non-antibiotic approaches and improved molecular diagnostics, while not currently comprehensive, could revolutionise the field.
10mins - Expert presentations By Marta Boffito
Women and HIV
Dr Marta Boffito reviews options for managing co-morbities in women living with HIV. In particular, she discusses the importance of screening and the challenges of drug-drug for women taking anti-HIV medication.
11mins - Expert presentations By Professor Laura Bowater
Antimicrobial resistance: antibiotic stewardship in the UK
Professor Laura Bowater sets the scene with the global threat of antimicrobial resistance (AMR). She discusses the causes of AMR, and how antibiotic stewardship can prevent it's spread. Responsible usership, auditing and a strong clinical leadership are all key components of antibiotic stewardship.
12mins - Expert presentations
Antimicrobial resistance: epidemiology and experience in the UK
Dr Matt O'Shea and Dr Ed Bevan discuss the basic mechanisms of antimicrobial resistance and the predicted clinical cost in the UK. They elaborate on the epidemology of a number of known and prevelant resistant bacterium in the UK and explain how antimicrobial stewardship, screening and surveillance are helping to prevent the spread of such bacteria. Finally, they discuss a real patient case.
12mins - Expert presentations By Graeme Moyle
HIV and comorbidities in older subjects
In this expert presentation, Dr Graeme Moyle from the Chelsea and Westminster Hospital in London discusses the current recommendations for HIV patients >50 years old. Just like the general ageing population, people with HIV develop comorbidities such as cardiovascular disease, diabetes, bone disease, liver disease and other non-communicable diseases. In this expert presentation Dr Moyle reviews how addressing these comorbidities is crucial and the European Guidelines for treatment of HIV-positive adults in Europe (EACS) provide a clear guide.
10mins - Expert presentations By Pr William Jacot
Molecular diversity of breast cancer From biological definitions to treatment implications
The topics of this talk will focus on the molecular diversity of breast cancers, from the classical subgroups based on ER, PR and HER2 status to emerging biomarkers, namely PIK3CA mutations, TOP2A amplification and BRCA1/2 mutations in the field of breast cancer treatment and tailoring of prognosis and therapy.
15mins - Expert presentations By Mark Verrill
Recent Advances in Neoadjuvant Chemotherapy for Early Breast Cancer
Neoadjuvant therapy is now standard practice in the treatment of patients with early breast cancer. Neoadjuvant therapies have been tested in increasingly innovative ways and typically use pathologic complete response (pCR) as a surrogate for long-term outcomes. Trials of neoadjuvant therapy have several advantages to trials in other settings, not least because pCR is available within months, with a relatively small sample size. These trials can therefore be used to facilitate early adoption of active new therapies in early breast cancer, and are also providing important information for research. Mark Verrill gives a medical oncologist’s view of the principles behind neoadjuvant trials in early breast cancer and the patients in whom neoadjuvant therapy is most beneficial. He also discusses the results of some of the most important findings of recent trials, including the adaptive I-SPY2 trial.